Summary by Moomoo AI
HANSEN PHARMACEUTICAL GROUP CO., LTD. ANNOUNCED THAT ITS INDEPENDENTLY DEVELOPED NEW TYPE 1 DRUG “HS-10509 TABLETS” HAS RECEIVED THE NOTICE OF CLINICAL TRIAL APPROVED BY CHINA'S NATIONAL DRUG ADMINISTRATION. This medicinal product is used to treat schizophrenia. Specific indications will be determined after clinical trials. This announcement was issued by the Board of Directors of Hanssen Pharmaceutical Group Limited on 17 January 2024. The members of the Board include Chairman and Executive Director Ms. Chung Wai-juan, Executive Directors Mr. Lu Aifeng and Ms. Sun Yuan; and Independent Non-Executive Directors Mr. Lin Qiangguo, Mr. Chen Shangwei and Ms. Yang Dongtao.